Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir

Biochemical and Biophysical Research Communications

Volumn 417, Issue 1, 2012, Pages 223-230

  Santiago, Francisco ^a   Oguma, Junya ^a   Brown, Anthony M C ^a   Laurence, Jeffrey ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Catenin; Human immunodeficiency virus; Osteoclast; Pathogenesis; Protease inhibitor; Wnt signaling

Indexed keywords

BETA CATENIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECOMBINANT PROTEIN; RITONAVIR; WNT3A PROTEIN; WNT5A PROTEIN; WNT5B PROTEIN;

ANIMAL CELL; ARTICLE; BONE DENSITY; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RETROVIRUS; UPREGULATION; WNT SIGNALING PATHWAY;

ANIMALS; BONE DENSITY; CELL DIFFERENTIATION; CELL LINE; HEK293 CELLS; HIV PROTEASE INHIBITORS; HUMANS; MICE; OSTEOCLASTS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RECOMBINANT PROTEINS; RITONAVIR; WNT PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS; MURINAE;

EID: 84855802723     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.11.089     Document Type: Article

References (26)

1. Baron R., Rawadi G. Minireview: targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148:2635-2643.
2. Goldring S.R., Goldring M.B. Eating bone or adding it: the Wnt pathway decides. Nat. Med. 2007, 13:113-114.
3. Almeida M., Han L., Bellido T., Manolagas S.C., Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by β-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. J. Biol. Chem. 2005, 280:41342-41351.
4. Spencer G.J., Utting J.C., Etheridge S.L., Arnett T.R., Genever P.G. Wnt signaling in osteoblasts regulates expression of the receptor activator of NFκB ligand and inhibits osteoclastogenesis in vitro. J. Cell Sci. 2006, 19:1283-1296.
5. Glass D.A., Karsenty G. Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. Ann. NY Acad. Sci. 2006, 1068:117-130.
6. Monaghan H., Bubb V.J., Sirimujalin R., Millward-Sadler S.J., Salter D.M. Adenomatous polyposis coli (APC), β-catenin, and cadherin are expressed in human bone and cartilage. Histopathology 2001, 39:611-619.
7. Maeda K., Kobayashi Y., Ishihara A., Uehara S., Takada I., Kato S., Nishita M., Minami Y., Marumo K., Udagawa N., Takahashi N. Ror2 signaling enhances osteoclast formation in physiological and pathological conditions. Bone 2009, 44:S50. (Abstract).
8. Duvivier C., Kolta S., Assoumou L., Ghosn J., Rozenberg S., Murphy R.L., Katlama C., Costagliola D. Greater decrease in bone mineral density with protease inhibitor regimens compared with non-nucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naïve patients. AIDS 2009, 23:817-824.
9. Fakruddin J.M., Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor κB ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-γ/RANKL cross-talk. J. Biol. Chem. 2003, 278:48251-48258.
10. Modarresi R., Xiang Z., Yin M., Laurence J. Wnt/β-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss. Am. J. Pathol. 2009, 174:123-135.
11. Topol L., Jiang X., Choi H., Garrett-Beal L., Carolan P.J., Yang Y. Wnt5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J. Cell Biol. 2003, 162:899-908.
12. Kanazawa A., Tsukada S., Kamiyama M., Yanagimoto T., Nakajima M., Maeda S. Wnt5b partially inhibits canonical Wnt/β-catenin signaling pathway and promotes adipogenesis in 3T3-L1 preadipocytes. BBRC 2005, 330:505-510.
13. Mikels A.J., Nusse R. Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling dependent on receptor context. PloS Biol. 2006, 4:e115.
14. Sato A., Yamamoto H., Sakane H., Koyama H., Kikuchi A. Wnt5a regulates distinct signaling pathways by binding to Frizzled2. EMBO J. 2009, 29:41-54.
15. Fradkin L.G., Dura J.-M., Noordermeer J.N. Ryks: new partners for Wnts in the developing and regenerating nervous system. Trends Neurosci. 2010, 33:84-92.
16. Mikels A., Minami Y., Nusse R. Ror2 receptor requires tyrosine kinase activity to mediate Wnt5a signaling. J. Biol. Chem. 2009, 284:30167-30176.
17. Angers S., Moon R.T. Proximal events in Wnt signal transduction. Nat. Rev. Mol. Cell Biol. 2009, 10:468-477.
18. von Amerongen R., Mikels A., Nusse R. Alternative Wnt signaling is initiated by distinct receptors. Sci. Signal. 2008, 1:re9.
19. Masckauchan T.N.H., Agalliu D., Vorontchikhina M., Ahn A., Parmalee N.L., Li C.-M., Khoo A., Tycko B., Brown A.M.C., Kitajewski J. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol. Biol. Cell 2006, 17:5163-5172.
20. van Tienen F.H.J., Laeremans H., van der Kallen C.J.H., Sweets H.J.M. Wnt5b stimulates adipogenesis by activating PPARγ, and inhibiting the β-catenin dependent Wnt signaling pathway together with Wnt5a. BBRC 2009, 387:207-211.
21. Grigsby I.F., Pham L., Mansky L.M., Gopalakrishnan R., Carlson A.E., Mansky K.C. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. BBRC 2010, 394:48-53.
22. Saitoh T., Katoh M. Expression and regulation of Wnt5a andWnt5b byTNF-α in MKN45 cells and up-regulation of Wnt5b by β-estradiol in MCF-7 cells. Int. J. Mol. Med. 2002, 10:345-349.
23. Syed F., Huang C.C., Li K., Liu V., Shang T., Amegadzie B.Y., Griswold D.E., Song X.-Y., Li L. Identification of interleukin-13 related biomarkers using peripheral blood mononuclear cells. Biomarkers 2007, 12:414-423.
24. Yin M.T., Modarresi R., Shane E., Santiago F., Ferris D.C., McMahon D.J., Zhang C.A., Cremers S., Laurence J. Effects of HIV infection and antiretroviral therapy with ritonavir on induction of osteoclast-like cells in postmenopausal women. Osteoporosis Int. 2011, 22:1459-1468.
25. Bonjoch A., Figueros M., Estany C., Perez-Alvarez N., Rosales J., DelRio L., di Gregorio S., Puig J., Gomez G., Clotel B., Negredo E. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010, 24:2827-2833.
26. Malizia A.P., Cotter E., Crew N., Powderly W.G., Doran P.P. HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts. AIDS Res. Human Retrov. 2008, 23:243-250.